NIP
VRDN icon

Nicholas Investment Partners’s Viridian Therapeutics VRDN Stock Holding History

Nicholas Investment Partners’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-124,257
Closed -$2.43M – 239
2026
Q1 		$2.43M Buy
124,257
+57,175
+85% +$1.7M 0.18% 151
2025
Q4 		$2.09M Buy
+67,082
New +$1.84M 0.15% 152

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Nicholas Investment Partners's VRDN Position: Q2 2026 in Review

Nicholas Investment Partners sold out of Viridian Therapeutics (VRDN) in Q2 2026, closing a stake of 124,257 shares — an estimated $2.43M sold.

Nicholas Investment Partners first reported a position in VRDN in Q4 2025 and held it in 2 quarters. The position peaked at $2.43M in Q1 2026. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Nicholas Investment Partners reported no remaining Viridian Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Nicholas Investment Partners sold 124,257 Viridian Therapeutics shares in Q2 2026, an estimated $2.43M.
  • Nicholas Investment Partners first reported a position in Viridian Therapeutics in Q4 2025 and held it in 2 quarters.
  • Nicholas Investment Partners's Viridian Therapeutics position peaked at $2.43M in Q1 2026.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Nicholas Investment Partners's 13F filing for Q2 2026, filed 14 Aug 2026.